Friday, October 30, 2026

North Korea Marks Day of Songun, Hails Military Legacy of Kim Jong Il and Kim Jong Un

North Korea celebrated the Day of Songun, emphasizing Kim Jong Il's military initiatives and Kim Jong Un's leadership in strengthening the armed forces.

NVIDIA’s Jensen Huang Expands AI Alliances with SK, LG, and Hyundai: What This Means for the Future of AI in Korea

NVIDIA's CEO Jensen Huang forms AI alliances with major Korean firms to enhance AI infrastructure, robotics, and cloud services.

U.S. Senator Pushes for Warship Construction by Allies, Highlights South Korea’s Key Role

Senator Mike Lee advocates outsourcing U.S. warship construction to allies, highlighting South Korea's crucial role in meeting Navy demands.

Jung Eun Kim

Author's Latest

Cancer Gone for 3 Years? This New Drug Is Making It Happen

AbbVie's Epkinly shows 96% long-term complete remission in R/R large B-cell lymphoma patients, highlighting its effectiveness as a therapy.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

Opdivo Wins EU Approval in Big Step for Early Lung Cancer Treatment

Opdivo gains EU approval for perioperative therapy in NSCLC, enhancing competition with Keytruda and marking a treatment paradigm shift.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk and Lilly Block Generics, Tighten Grip on $125B GLP-1 Market

Novo Nordisk and Eli Lilly secure court victories against generics, maintaining dominance in the GLP-1 treatment market amid rising demand.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

President Yoon Announces Historic Oil Discovery in South Korea

After President Yoon announced the "potential for a massive amount of oil and natural gas reserves off Pohang," oil stocks have risen.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.